UBE3C and head and neck cancer: For instance, recent studies have suggested that the expression of the UBE3C-LRP5 fusion protein may serve as a potential therapeutic target for head and neck cancer, and pyrroloquinoline quinone may emerge as a promising drug candidate for treating this malignancy [23].